Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307851 · ClinicalTrials.gov registry record · Phase 2
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT02307851 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 400 participants.
The verdict
NCT02307851, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the immune response of three dose levels of the Quadrivalent VLP vaccine in healthy young (18-49) adults. The study is broken down into four treatment groups. Each group will enroll 100 subjects, for a total of 400 subjects. Groups A-C will receive one of three dose levels of the Quadrivalent VLP vaccine, and Group D will receive a commercially available trivalent influenza vaccine (TIV). The study will also evaluate the safety and tolerability of the Quadrivalent VLP vaccine formulations.
Interventions
- BIOLOGICAL Quadrivalent VLP Vaccine
- BIOLOGICAL Comparator TIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02307851
The ClinicalTrials.gov registry entry for NCT02307851 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quadrivalent VLP Vaccine is the first listed.
NCT02307851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02307851 about?
NCT02307851 is a clinical study titled "Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults". The purpose of this study is to determine the immune response of three dose levels of the Quadrivalent VLP vaccine in healthy young (18-49) adults. The study is broken down into four treatment groups. Each group will enroll 100 subjects, for a total of 400 subjects. Groups A-C will receive one of th...
What is the current status of trial NCT02307851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2014-11. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02307851?
The interventions under investigation include: Quadrivalent VLP Vaccine (BIOLOGICAL), Comparator TIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02307851?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.